Nurse Practitioner in Penn Valley, PA Accepting Medicare
5 Nurse Practitioner nurses found. Showing 1 - 5
 Mrs. Sarah B. Klein, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 915 Montgomery Ave Ste 400, Penn Valley, PA 19072 Phone: 484-476-3078 |
Clementina Nkiru Okorji, MSN, AGNP-C Nurse Practitioner - Gerontology Medicare: Accepting Medicare Assignments Practice Location: 857 Montgomery Ave, Penn Valley, PA 19072 Phone: 610-664-2951 |
Mrs. Eve Bosnick, MSN,CRNP Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 701 Montgomery Ave, Penn Valley, PA 19072 Phone: 610-642-9200 |
Elianne Josel, CRNP Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 701 Montgomery Ave Ste 18, Penn Valley, PA 19072 Phone: 610-642-9200 Fax: 610-649-4723 |
Jordana Faith Popovich, CRNP Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 701 Montgomery Ave, Suite 18, Penn Valley, PA 19072 Phone: 610-642-9200 Fax: 610-649-4723 |
News Archive
The third "Exciting Biologies" meeting focuses on "Biology In Balance"
In a continuing series called "Exciting Biologies" Cell Press, Massachusetts General Hospital and La Fondation Ipsen collaborate to offer annual meetings designed to highlight emerging intersections in biomedical research and promote interactions between scientists from converging disciplines. This third meeting, held in Buenos Aires between the 8th and 10th of October, focused on "Biology in Balance".
Virobay announces closing of expanded Series B second tranche financing
Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million.
DCC gene protects mice from onset of colon cancer
The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.
Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs
Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration.
› Verified 8 days ago